ART Time Domain Technology Applications to Be Presented at the Photonics West Conference in San Jose, California
19 January 2008 - 4:53AM
Marketwired
MONTREAL, CANADA (TSX: ARA), a Canadian medical device company
and a leader in optical molecular imaging products for the
healthcare and pharmaceutical industries, will be presenting five
papers at the Photonics West/BiOS symposium, being held at the San
Jose Convention Center in California, from January 19 to 24,
2008.
Scientific presentations featuring research based on ART's
SoftScan� optical imaging device and the Optix� in vivo
fluorescence optical imaging system include:
Oral Presentation Number: 6850-2. Fluorescence lifetime
estimation of multiple near-infrared dyes in mice. Guobin Ma, Simon
Fortier, Muriel Jean-Jacques, Niculae Mincu, Zahia Ichalalene,
Frederic Leblond, Anader Benyamin-Seeyar, Mario Khayat, ART
Advanced Research Technologies, Canada. Saturday, January 19, 2008,
9:10 am-9:30 am, Convention Center.
Oral Presentation Number: 6850-4. Characterization of natural
fluorescence in mice. Salim Djeziri, Guobin Ma, Niculae Mincu,
Anader Benyamin-Seeyar, ART Advanced Research Technologies, Canada.
Saturday, January 19, 2008, 9:50 am-10:10 am, Convention
Center.
Oral Presentation Number: 6850-12. Design and performance
analysis of a small-animal fluorescence tomography system coupled
to MicroCT. Dax S. Kepshire1, Michael Hutchins2, Annie Provencher2,
Niculae Mincu2, Frederic Leblond2, Brian W. Pogue1, Mario Khayat2,
1Dartmouth College, 2ART Advanced Research Technologies, Canada.
Saturday, January 19, 2008, 2:10 pm-2:30 pm, Convention Center.
Poster Presentation Number: 6854-62. Full path Monte-Carlo
simulation of fluorescence in non-voxelized complex heterogeneous
mouse model. Jean-Francois Delorme, Guobin Ma, Frederic Lesage,
Frederic Leblond, Anader Benyamin-Seeyar, Mario Khayat, ART
Advanced Research Technologies, Canada. Monday, January 21, 2008,
6:00 pm-7:30 pm, Civic Auditorium.
Oral Presentation Number: 6870-24. Diffuse optical tomography
and spectroscopy performance assessment: phantoms and methodology.
Niculae Mincu, Jean Brunette, Olga Guilman, Frederic Leblond, Salim
Djeziri, Zahia Ichalalene, Guobin Ma, Mario Khayat, Anader
Benyamin-Seeyar, ART Advanced Research Technologies, Canada.
Sunday, January 20, 2008, 9:50 am-10:10 am, Convention Center.
Full texts of the abstracts can be obtained through the
Photonics West/BiOS meeting program page
(http://spie.org/x2595.xml) and following the link labeled "Search
Program".
The Photonics West symposium, organized by the International
Society of Optical Engineering, leads the way in the development
and transfer of important light-enabled technologies, such as
biomedical optics, and lasers and applications in science and
engineering. For more information on this event, visit:
http://spie.org/events/pw.
About ART
ART Advanced Research Technologies Inc. is a leader in molecular
imaging products for the healthcare and pharmaceutical industries.
ART has developed products in medical imaging, medical diagnostics,
disease research, and drug discovery with the goal of bringing new
and better treatments to patients faster. The Optix� optical
molecular imaging system, designed for monitoring physiological
changes in living systems at the preclinical study phases of new
drugs, is distributed directly by ART and is used by industry and
academic leaders worldwide. The SoftScan� optical breast imaging
device is designed to improve the diagnosis and treatment of breast
cancer. ART is commercializing the SoftScan optical medical imaging
device via a global strategic alliance with GE Healthcare, a world
leader in mammography and imaging. Finally, the Fenestra� line of
molecular imaging contrast products provide image enhancement for a
wide range of preclinical Micro CT applications allowing scientists
to see greater detail in their imaging studies, with potential
extension into other major imaging modalities. The distribution of
the Fenestra line of imaging contrast agents is made through GE
Healthcare Bio-Science KK in Japan and is sold directly by the
Company in the rest of the world. ART's shares are listed on the
TSX under the ticker symbol ARA. For more information on ART, visit
our website at www.art.ca.
This press release may contain forward-looking statements
subject to risks and uncertainties that would cause actual events
to differ materially from expectations. These risks and
uncertainties are described in the most recent Annual Information
Form and the financial statements for the year ended December 31,
2006, available on SEDAR (www.sedar.com).
Contacts: ART Advanced Research Technologies Inc. Jacques Bedard
Chief Financial Officer jbedard@art.ca ART Advanced Research
Technologies Inc. Mario Khayat Vice President, Optical Products
514-832-0777 www.art.ca
Aclara Resources (TSX:ARA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aclara Resources (TSX:ARA)
Historical Stock Chart
From Jul 2023 to Jul 2024